REGENXBIO Inc. News
Too Much Risk?: Cramer's 'Mad Money' Recap (Friday 1/10/20)
As we leap into earnings season, Jim Cramer look at profits, trade, employment, inflation and whether this rally is worth the risk. Here's your game plan for next week.
Stay on Top of Your Game: Cramer's 'Mad Money' Recap
Jim Cramer says investors need to stay vigilant, despite recent market gains. He's got your game plan for next week.
Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers
Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.
Novocure Shares Jump On Phase 3 Data - Biotech Movers
The St. Helier, Jersey-based firm said a Phase 3 study of Optune in tandem with temozolomide in newly diagnosed glioblastoma "demonstrated unprecedented five-year survival results."
Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers
Ultragenyx Pharmaceutical made a proposal to acquire Dimension Therapeutics, which last month agreed to sell to Regenxbio.
Regenxbio Leads Biotech Movers Ahead of Market's Open
Also on the move were Global Blood Therapeutics, Valeant and Kite Pharma, among others.
Beleaguered valeant appoints lead independent director
Thomas Ross Sr.'s other endeavors include his recent appointment as president of The Volcker Alliance.
Oil Prices Bounce From 9-Month Lows As Hurricane Ian Clips Gulf Production
"Hopefully, disruptions will be very limited due to Ian, but there remain many factors driving prices both up and down across the country,” said Gasbuddy's Patrick De Haan.
Tim Cook and Apple Make a Move That Could Annoy China
iPhone maker wants to diversify its supply chain and expand in a crucial market.